Sanofi to buy Inhibrx for $2.2 billion in rare disease push

The acquisition is the latest in a string of small- and mid-sized deals as Sanofi looks to double down on innovative medicines and reduce its reliance on the blockbuster asthma medicine Dupixent.

Related Keywords

Paris ,France General ,France ,French ,Mark Lappe ,Paul Hudson ,Thibault Boutherin ,Roche Holding ,Morgan Stanley ,Inhibrx Inc ,Enhanced Potential ,California Based Inhibrx ,World News ,Sanofi ,Inhibrx ,Disease ,